GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Talazoparib capsules (Talzenna)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

TALZENNA - talazoparib capsules

Product / population
TALZENNA: distinguish breast-cancer monotherapy from HRR-mutated mCRPC with enzalutamide.
Renal method
CrCl, mL/min
Source revision
6/2025
Retrieved
2026-09-10
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Dose disagreement: moderate-renal mCRPC instruction

The RX mirror and exact official label differ for moderate-renal mCRPC dosing with enzalutamide. The disputed mirror extract is documentation, not permission.

What to reconcile: Read the newly dated official section and have oncology/pharmacy adjudicate the discrepancy. Do not average doses or confuse breast-cancer and mCRPC regimens.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references

The moderate-renal mCRPC dose disagreement is still present

The current official label states 0.35 mg daily with enzalutamide at CrCl 30-59; the retrieved RX mirror still states 0.5 mg daily for that setting. Breast-cancer monotherapy is a separate regimen.

What to reconcile: Keep the conflict flagged and prioritize the exact official product label; do not average the doses or transfer the monotherapy schedule.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Official

TALZENNA - talazoparib capsules

Open original reference

DailyMed / Pfizer Inc. · TALZENNA: distinguish breast-cancer monotherapy from HRR-mutated mCRPC with enzalutamide.

Renal method: CrCl, mL/min
Source date: 6/2025
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For mCRPC with enzalutamide, CrCl 30-59 mL/min requires 0.35 mg once daily; CrCl 15-29 requires 0.25 mg once daily. Breast-cancer monotherapy uses 0.75 mg daily at 30-59 and 0.5 mg daily at 15-29. These are separate indication-specific renal regimens.

Hemodialysis has not been studied. Review hematologic toxicity and interacting drugs separately. This dated official renal paragraph does not resolve the mirror's different moderate-renal mCRPC amount by averaging; the mirror remains flagged.

RDM57-official-talazoparib-talzenna-6020d48257-C1 · Source locator: Sections 2.6 and 8.7

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections checked. Raw SPL XML, original document hash and complete revision history were not obtained.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2423edd-6d24-495c-aec1-c2f457f08d9a
Retrieved
2026-09-10
Exact label title
TALZENNA - talazoparib capsules
DailyMed Set ID
f2423edd-6d24-495c-aec1-c2f457f08d9a
Labeler
Pfizer Inc.
Label revision
6/2025
Renal-function method
CrCl, mL/min
Source date/version
6/2025
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
adf5cac0e9143ccaaf540fc95ef8bad564a4b76210b3cfa36d02cac6349f68ba

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=talazoparib-talzenna&s1=RDM57-official-talazoparib-talzenna-6020d48257&h1=236e40b7f6c2a5693b4ed417000c1ab075c1180fc72c137ac8aa8af39ec50eda